Td Asset Management Inc Argenx Se Transaction History

Td Asset Management Inc

$107 Billion
Q3 2024

A detailed history of Td Asset Management Inc transactions in Argenx Se stock. As of the latest transaction made, Td Asset Management Inc holds 180,670 shares of ARGX stock, worth $112 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

180,670

Previous 212,128 14.83%

Holding current value

$112 Million

Previous $91.2 Million 7.41%

% of portfolio

0.09%

Previous 0.09%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$434.22 - $551.9 $13.7 Million - $17.4 Million	-31,458 Reduced 14.83%	180,670 $98 Million
Q2 2024 Aug 02, 2024	SELL	$356.01 - $451.55 $4.12 Million - $5.22 Million	-11,567 Reduced 5.17%	212,128 $91.2 Million
Q1 2024 May 08, 2024	BUY	$356.95 - $413.29 $10.6 Million - $12.3 Million	29,810 Added 15.38%	223,695 $88.1 Million
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $6.27 Million - $9.37 Million	18,514 Added 10.56%	193,885 $73.8 Million
Q3 2023 Oct 27, 2023	BUY	$369.35 - $548.43 $19.1 Million - $28.4 Million	51,791 Added 41.91%	175,371 $86.2 Million
Q2 2023 Aug 09, 2023	BUY	$360.14 - $422.58 $2.34 Million - $2.75 Million	6,510 Added 5.56%	123,580 $48.2 Million
Q1 2023 May 10, 2023	SELL	$334.23 - $403.65 $4.01 Million - $4.84 Million	-12,000 Reduced 9.3%	117,070 $43.6 Million
Q4 2022 Feb 06, 2023	SELL	$342.17 - $402.31 $22.7 Million - $26.7 Million	-66,327 Reduced 33.94%	129,070 $48.9 Million
Q3 2022 Nov 07, 2022	SELL	$343.2 - $395.75 $2.61 Million - $3.01 Million	-7,618 Reduced 3.75%	195,397 $69.9 Million
Q2 2022 Aug 04, 2022	SELL	$269.58 - $378.88 $1.86 Million - $2.61 Million	-6,890 Reduced 3.28%	203,015 $76.9 Million
Q1 2022 May 10, 2022	BUY	$254.45 - $351.06 $2.3 Million - $3.17 Million	9,027 Added 4.49%	209,905 $66.2 Million
Q4 2021 Feb 10, 2022	BUY	$272.01 - $353.03 $17.7 Million - $23 Million	65,117 Added 47.96%	200,878 $70.3 Million
Q3 2021 Nov 09, 2021	BUY	$295.0 - $350.58 $926,300 - $1.1 Million	3,140 Added 2.37%	135,761 $41 Million
Q2 2021 Aug 11, 2021	SELL	$257.11 - $319.92 $1.21 Million - $1.51 Million	-4,716 Reduced 3.43%	132,621 $40.4 Million
Q1 2021 May 14, 2021	BUY	$268.3 - $380.31 $4.52 Million - $6.41 Million	16,854 Added 13.99%	137,337 $37.8 Million
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $1.52 Million - $1.89 Million	6,128 Added 5.36%	120,483 $35.4 Million
Q3 2020 Nov 10, 2020	BUY	$215.51 - $272.51 $457,743 - $578,811	2,124 Added 1.89%	114,355 $30 Million
Q2 2020 Aug 13, 2020	BUY	$127.44 - $232.72 $3.48 Million - $6.36 Million	27,324 Added 32.18%	112,231 $25.3 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $761,810 - $1.16 Million	-7,000 Reduced 7.62%	84,907 $11.2 Million
Q4 2019 Feb 11, 2020	BUY	$106.59 - $164.21 $149,226 - $229,894	1,400 Added 1.55%	91,907 $14.8 Million
Q3 2019 Nov 07, 2019	BUY	$113.31 - $150.51 $305,937 - $406,377	2,700 Added 3.07%	90,507 $10.3 Million
Q2 2019 Aug 01, 2019	BUY	$115.0 - $141.58 $545,905 - $672,080	4,747 Added 5.72%	87,807 $12.4 Million
Q1 2019 May 08, 2019	BUY	$98.85 - $134.59 $3.27 Million - $4.45 Million	33,082 Added 66.19%	83,060 $10.4 Million
Q4 2018 Feb 01, 2019	BUY	$63.81 - $109.82 $223,335 - $384,370	3,500 Added 7.53%	49,978 $4.8 Million
Q3 2018 Nov 01, 2018	BUY	$75.5 - $96.63 $577,273 - $738,832	7,646 Added 19.69%	46,478 $3.53 Million
Q2 2018 Jul 31, 2018	BUY	$74.84 - $100.16 $220,927 - $295,672	2,952 Added 8.23%	38,832 $3.22 Million
Q1 2018 May 11, 2018	BUY	$56.95 - $85.19 $1.1 Million - $1.64 Million	19,255 Added 115.82%	35,880 $2.89 Million
Q4 2017 Feb 02, 2018	BUY	$22.57 - $63.56 $375,226 - $1.06 Million	16,625	16,625 $1.05 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Argenx Se Transaction History